Related Experiment Video
Updated: Jul 4, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
1Institut für Naturheilkunde und Klinische Pharmakologie, Universität Ulm, Helmholtzstrasse 20, 89081 Ulm, Deutschland.
Der Internist
|June 14, 2008
Summary
Genetic variations in drug-metabolizing enzymes like CYP2D6, CYP2C9, and CYP2C19 significantly impact drug efficacy and safety. Understanding these pharmacogenetic traits enables personalized drug selection and dosage for improved patient outcomes.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Genomics
Background:
- Drug therapy efficacy is influenced by patient-specific factors including genetics.
- Genetic polymorphisms in drug-metabolizing enzymes can lead to altered drug responses.
- Cytochrome P450 enzymes (CYP2D6, CYP2C9, CYP2C19) are key in metabolizing many common medications.
Purpose of the Study:
- To highlight the impact of pharmacogenetic variations on drug metabolism.
- To emphasize the clinical relevance of identifying genetic polymorphisms before prescribing.
- To advocate for personalized medicine approaches in drug therapy.
Main Methods:
- Review of literature on drug metabolism and genetic polymorphisms.
- Identification of key polymorphic enzymes (CYP2D6, CYP2C9, CYP2C19).
- Analysis of drug classes metabolized by these enzymes.
Main Results:
- Genetic polymorphisms cause slow or fast drug metabolism, increasing risks of adverse drug reactions or therapeutic failure.
- Specific CYP enzymes metabolize a wide range of drugs, including cancer therapies, PPIs, NSAIDs, and more.
- Genotyping can predict individual drug response based on genetic makeup.
Conclusions:
- Knowledge of pharmacogenetic profiles is crucial for optimizing drug therapy.
- Personalized drug selection and dosage based on genotyping can improve safety and efficacy.
- Pharmacogenetics offers a pathway to precision medicine for a broad spectrum of treatments.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...